
Patent Claims

1. Compounds of the formula I



I

in which

R^1 denotes H, Hal, CH_3, OCH_3 or CH_2OH,

X denotes Ar or Cyc,

Ar denotes phenyl, biphenyl or naphthyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, NO_2, CN, A, $[C(R^2)_2]_pOR^2$, $S(O)_mR^2$, $[C(R^2)_2]_pN(R^2)_2$, $[C(R^2)_2]_pCOOR^2$, $[C(R^2)_2]_pCON(R^2)_2$, $[C(R^2)_2]_pSO_2N(R^2)_2$, NR^2COR^2, $NR^2SO_2R^2$, $NR^2CON(R^2)_2$, NHCOOA, $O[C(R^2)_2]_nN(R^2)_2$, CHO and/or COA,

R^2 denotes H oder A,

A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH_2-groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by F, Cl and/or OH,

Cyc denotes cycloalkyl with 3, 4, 5, 6 or 7 C-atoms,

Hal denotes F, Cl, Br or I,

m denotes 0, 1 or 2,

n denotes 1, 2 or 3,

p denotes 0, 1, 2, 3 or 4,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

R^1 denotes H, Hal or CH_3,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, NO_2, CN, A and/or $[C(R^2)_2]_pOR^2$,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which

A denotes unbranched or branched alkyl with 1-6 C-atoms, wherein 1-5 H-atoms may be replaced by F,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to Claim 1, in which

R^1 denotes H, Hal or CH_3,

X denotes Ar or Cyc,

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, NO_2, CN, A and/or $[C(R^2)_2]_pOR^2$,

R^2 denotes H oder A,

Cyc denotes cycloalkyl with 3, 4, 5, 6 or 7 C-atoms,

A denotes unbranched or branched alkyl with 1-6 C-atoms, wherein 1-5 H-atoms may be replaced by F,

Hal denotes F, Cl, Br or I,

p denotes 0, 1, 2, 3 or 4,

n denotes 1, 2 or 3,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to Claim 1, selected from the group


No.	Name
"A1"	2-phenyl-N-phthalazin-1-yl-acetamide
"A2"	2-(3-methoxyphenyl)-N-phthalazin-1-yl-acetamide
"A3"	2-(4-methoxyphenyl)-N-phthalazin-1-yl-acetamide
"A4"	2-(4-ethoxyphenyl)-N-phthalazin-1-yl-acetamide
"A5"	N-phthalazin-1-yl-2-(3-trifluoromethoxyphenyl)-acetamide
"A6"	2-(3-cyanophenyl)-N-phthalazin-1-yl-acetamide
"A7"	2-(3-nitrophenyl)-N-phthalazin-1-yl-acetamide
"A8"	N-phthalazin-1-yl-2-(4-trifluoromethoxyphenyl)-acetamide
"A9"	2-(4-*tert*-butylphenyl)-N-phthalazin-1-yl-acetamide
"A10"	2-(2,6-dichlorophenyl)-N-phthalazin-1-yl-acetamide
"A11"	2-(4-ethoxy-phenyl)-N-(5-fluoro-phthalazin-1-yl)-acetamide
"A12"	N-(5-fluoro-phthalazin-1-yl)-2-(4-methoxy-phenyl)-acetamide
"A13"	3-cyclohexyl-N-phthalazin-1-yl-propionamide
"A14"	3-phenyl-N-phthalazin-1-yl-propionamide
"A15"	3-cyclopentyl-N-phthalazin-1-yl-propionamide
"A16"	3-(2-chloro-phenyl)-N-phthalazin-1-yl-propionamide
"A17"	3-(2,3-dichloro-phenyl)-N-phthalazin-1-yl-propionamide
"A18"	N-(8-methyl-phthalazin-1-yl)-2-phenyl-acetamide
"A19"	N-(5-methyl-phthalazin-1-yl)-2-phenyl-acetamide
"A20"	2-(4-methoxy-phenyl)-N-(8-methyl-phthalazin-1-yl)-acetamide
"A21"	2-(4-methoxy-phenyl)-N-(5-methyl-phthalazin-1-yl)-acetamide
"A22"	3-cyclohexyl-N-(8-methyl-phthalazin-1-yl)-propionamide
"A23"	3-phenyl-N-(8-methyl-phthalazin-1-yl)-propionamide

"A24"	3-cyclopentyl-N-(8-methyl-phthalazin-1-yl)-propionamide
"A25"	3-(2-chlorophenyl)-N-(8-methyl-phthalazin-1-yl)-propionamide
"A26"	3-(2,3-dichlorophenyl)-N-(8-methyl-phthalazin-1-yl)-propionamide

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Process for the preparation of compounds of the formula I according to Claims 1-6 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that

a compound of the formula II




II

in which R^1 has the meanings indicated in Claim 1,

is reacted

with a compound of formula III



III

in which X and n have the meanings indicated in Claim 1,

and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

8. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

9. Compounds of the formula I and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

10. Compounds according to claim 9 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.

11. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

12. Set (kit) consisting of separate packs of


(a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

Patent Claims

1. Compounds of the formula I



I

in which

R^1 denotes H, Hal, CH_3, OCH_3 or CH_2OH,

X denotes Ar or Cyc,

Ar denotes phenyl, biphenyl or naphthyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, NO_2, CN, A, $[C(R^2)_2]_pOR^2$, $S(O)_mR^2$, $[C(R^2)_2]_pN(R^2)_2$, $[C(R^2)_2]_pCOOR^2$, $[C(R^2)_2]_pCON(R^2)_2$, $[C(R^2)_2]_pSO_2N(R^2)_2$, NR^2COR^2, $NR^2SO_2R^2$, $NR^2CON(R^2)_2$, NHCOOA, $O[C(R^2)_2]_nN(R^2)_2$, CHO and/or COA,

R^2 denotes H oder A,

A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH_2-groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by F, Cl and/or OH,

Cyc denotes cycloalkyl with 3, 4, 5, 6 or 7 C-atoms,

Hal denotes F, Cl, Br or I,

m denotes 0, 1 or 2,

n denotes 1, 2 or 3,

p denotes 0, 1, 2, 3 or 4,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

R^1 denotes H, Hal or CH_3,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, NO_2, CN, A and/or $[C(R^2)_2]_pOR^2$,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which

A denotes unbranched or branched alkyl with 1-6 C-atoms, wherein 1-5 H-atoms may be replaced by F,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to Claim 1, in which

R^1 denotes H, Hal or CH_3,

X denotes Ar or Cyc,

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, NO_2, CN, A and/or $[C(R^2)_2]_pOR^2$,

R^2 denotes H oder A,

Cyc denotes cycloalkyl with 3, 4, 5, 6 or 7 C-atoms,

A denotes unbranched or branched alkyl with 1-6 C-atoms, wherein 1-5 H-atoms may be replaced by F,

Hal denotes F, Cl, Br or I,

p denotes 0, 1, 2, 3 or 4,

n denotes 1, 2 or 3,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to Claim 1, selected from the group


No.	Name
"A1"	2-phenyl-N-phthalazin-1-yl-acetamide
"A2"	2-(3-methoxyphenyl)-N-phthalazin-1-yl-acetamide
"A3"	2-(4-methoxyphenyl)-N-phthalazin-1-yl-acetamide
"A4"	2-(4-ethoxyphenyl)-N-phthalazin-1-yl-acetamide
"A5"	N-phthalazin-1-yl-2-(3-trifluoromethoxyphenyl)-acetamide
"A6"	2-(3-cyanophenyl)-N-phthalazin-1-yl-acetamide
"A7"	2-(3-nitrophenyl)-N-phthalazin-1-yl-acetamide
"A8"	N-phthalazin-1-yl-2-(4-trifluoromethoxyphenyl)-acetamide
"A9"	2-(4-*tert*-butylphenyl)-N-phthalazin-1-yl-acetamide
"A10"	2-(2,6-dichlorophenyl)-N-phthalazin-1-yl-acetamide
"A11"	2-(4-ethoxy-phenyl)-N-(5-fluoro-phthalazin-1-yl)-acetamide
"A12"	N-(5-fluoro-phthalazin-1-yl)-2-(4-methoxy-phenyl)-acetamide
"A13"	3-cyclohexyl-N-phthalazin-1-yl-propionamide
"A14"	3-phenyl-N-phthalazin-1-yl-propionamide
"A15"	3-cyclopentyl-N-phthalazin-1-yl-propionamide
"A16"	3-(2-chloro-phenyl)-N-phthalazin-1-yl-propionamide
"A17"	3-(2,3-dichloro-phenyl)-N-phthalazin-1-yl-propionamide
"A18"	N-(8-methyl-phthalazin-1-yl)-2-phenyl-acetamide
"A19"	N-(5-methyl-phthalazin-1-yl)-2-phenyl-acetamide
"A20"	2-(4-methoxy-phenyl)-N-(8-methyl-phthalazin-1-yl)-acetamide
"A21"	2-(4-methoxy-phenyl)-N-(5-methyl-phthalazin-1-yl)-acetamide
"A22"	3-cyclohexyl-N-(8-methyl-phthalazin-1-yl)-propionamide
"A23"	3-phenyl-N-(8-methyl-phthalazin-1-yl)-propionamide

"A24"	3-cyclopentyl-N-(8-methyl-phthalazin-1-yl)-propionamide
"A25"	3-(2-chlorophenyl)-N-(8-methyl-phthalazin-1-yl)-propionamide
"A26"	3-(2,3-dichlorophenyl)-N-(8-methyl-phthalazin-1-yl)-propionamide

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Process for the preparation of compounds of the formula I according to Claims 1-6 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that

a compound of the formula II




II

in which R^1 has the meanings indicated in Claim 1,

is reacted

with a compound of formula III



III

in which X and n have the meanings indicated in Claim 1,

and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

8. Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

9. Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

10. Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.